shutterstock_549156772_ken_wolter

Ken Wolter / Shutterstock.com

12 April 2022MedtechAlex Baldwin

Fed Circ revives claims in St Jude’s catheter patent suit

Abbot-owned St Jude Medical will have to defend claims that its catheters infringe a company’s revived patent.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Gilead ruling ‘threatens life-saving research’, says St Judes

18 November 2021 The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

St Jude recovers partial attorney fees in heart catheter case

26 October 2021 St Jude Medical will be able to claw back some of the attorney fees and expenses it incurred defending a suit filed by Niazi Licensing Corporation in a dispute over a patent covering a heart catheter.

More on this story

St Jude recovers partial attorney fees in heart catheter case

26 October 2021 St Jude Medical will be able to claw back some of the attorney fees and expenses it incurred defending a suit filed by Niazi Licensing Corporation in a dispute over a patent covering a heart catheter.

Gilead ruling ‘threatens life-saving research’, says St Judes

18 November 2021 The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

More on this story

St Jude recovers partial attorney fees in heart catheter case

26 October 2021 St Jude Medical will be able to claw back some of the attorney fees and expenses it incurred defending a suit filed by Niazi Licensing Corporation in a dispute over a patent covering a heart catheter.

Gilead ruling ‘threatens life-saving research’, says St Judes

18 November 2021 The US Court of Appeals for the Federal Circuit should revisit a ruling in favour of Gilead Sciences that invalidated a cancer drug patent because the decision jeopardises research, according to St Judes Children’s Research Hospital.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?